Pay in 4 interest-free payments of $6.67 Learn more
Ships within 48 hours · Estimated delivery Nov 4 - Nov 9
Eric Topol, MDs Post Two new studies zero in on the anti-inflammatory effects of the GLP-1 family of drugs, independent of weight loss, highlighting the gut-brain axis (modulating TLR response) and the gut GIP impact by Daniel Drucker and colleagues This opens up the possibility of using GLP-1 drugs in the treatment of long COVID or in conditions like schizophrenia that use the TLR pathway to activate neuroinflammation
Cost Considerations and Accessibility Both medications, accessible through healthcare providers and specialized programs like the Tracey Bell Clinics comprehensive support scheme, underscore an integrated approach to obesity and diabetes management, balancing affordability with effectiveness
Reduced Inflammation GLP-1 medications may: Lower inflammatory cytokines (like TNF- and IL-6) Shift immune cells toward a less inflammatory state This is important because lipedema tissue is characterized by chronic low-grade inflammation
Obesity affects over 40% of U.S
